Cargando…
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
BACKGROUND: Neratinib has efficacy in central nervous system (CNS) metastases from HER2‐positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capecitabine (N + C) versus lapatinib plus capecitabine (...
Autores principales: | Hurvitz, Sara A., Saura, Cristina, Oliveira, Mafalda, Trudeau, Maureen E., Moy, Beverly, Delaloge, Suzette, Gradishar, William, Kim, Sung‐Bae, Haley, Barbara, Ryvo, Larisa, Dai, Ming‐Shen, Milovanov, Vladimir, Alarcón, Jesús, Kalmadi, Sujith, Cronemberger, Eduardo, Souza, Cristiano, Landeiro, Luciana, Bose, Ron, Bebchuk, Judith, Kabbinavar, Fairooz, Bryce, Richard, Keyvanjah, Kiana, Brufsky, Adam M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342591/ https://www.ncbi.nlm.nih.gov/pubmed/34028126 http://dx.doi.org/10.1002/onco.13830 |
Ejemplares similares
-
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021) -
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021) -
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020) -
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
por: Dai, Ming Shen, et al.
Publicado: (2021) -
Nala y Damayanti /
Publicado: (1987)